Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-02
2007-10-02
Kemmerer, Elizabeth (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C435S001100
Reexamination Certificate
active
10664605
ABSTRACT:
The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5336759 (1994-08-01), Matsuo et al.
patent: 5338759 (1994-08-01), Shechter et al.
patent: 5434133 (1995-07-01), Tanaka et al.
patent: 5846932 (1998-12-01), Lowe et al.
patent: 5973134 (1999-10-01), Matsuo et al.
patent: 6020168 (2000-02-01), Matsuo et al.
patent: 6034231 (2000-03-01), Tanaka et al.
patent: 6329375 (2001-12-01), Tang et al.
patent: 6344459 (2002-02-01), Bridges et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 0 528686 (1993-02-01), None
patent: WO 00/61631 (2000-10-01), None
Druker and Lydon, J Clin Invest. 2000; 105: 3-7.
Suzuki et al. FEBS Letters, 1991; 282: 321-325.
Yabuta EP 0528686 A2, published Feb. 1993.
Rivera et al. Science 2000; 287: 826-830.
Mericq et al. J Clin Endocrinol Metab. 2000; 85: 569-73.
Hendy et al. Kidney Int. 2006; 69: 218-223.
Agrawal, S. et al., “Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice,”Proc. Natl. Acad. Sci. USA, vol. 88, pp. 7595-7599 (1991).
Brandt, R.R. et al., “Neutral Endopeptidase Regulates C-Type Natriuretic Peptide Metabolism But Does Not Potentiate Its Bioactivity In Vivo,”Hypertension, vol. 30, No. 2, pp. 184-190 (1997).
Chang, P.L., “Microcapsules as Bio-organs for Somatic Gene Therapy,”Annals New York Academy of Sciences, vol. 831, pp. 460-473 (1997).
Chen, H.H. et al., “C-Type Natriuretic Peptide: The Endothelial Component of the Natriuretic Peptide Systems,”J. of Cardiovasc. Pharmacol., vol. 32, Suppl. 3, pp. S22-S28 (1998).
Chen, H.H. et al., “Natriuretic Peptides in the Pathophysiology of Congestive Heart Failure,”Curr. Cadiol. Rev., vol. 2, pp. 198-205 (2000).
Chusho, H. et al., “Dwarfism and early death in mice lacking C-type natriuretic peptide,”PNAS, vol. 98, No. 7, pp. 4016-4021 (2001).
Fingl, E. et al., “Chapter 1—General Principles,” in The Pharmacological Basis of Therapeutics 5th edition, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).
Harvey, C.B. et al., “Molecular Mechanisms of Thyroid Hormone Effects on Bone Growth and Function,”Molecular Genetics and Metabolism, vol. 75, pp. 17-30 (2002).
Kelly, P.A. et al., “Growth Hormone Receptor Signalling and Actions in Bone Growth,”Hormone Research, vol. 55 (suppl. 2), pp. 14-17 (2001).
Kridel, S.J. et al., “Substrate Hydrolysis by Matrix Metalloproteinase-9,”J. Biol. Chem., vol. 276, No. 23, pp. 20572-20578 (2001).
Matsukawa, N. et al., “The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system,”Proc. Natl. Acad. Sci. USA, vol. 96, pp. 7403-7308 (1999).
McCarthy, T.L. et al., “Local IGF-I expression and bone formation,”Growth Hormone&IGF Research, vol. 11, pp. 213-219 (2001).
Mericq, V. et al., “Regulation of Fetal Rat Bone Growth by C-Type Natriuretic Peptide and cGMP,”Pediatric Research, vol. 47, No. 2, pp. 189-193 (2000).
Murthy, K.S. et al., “Identification of the G Protein-activating Domain of the Natriuretic Peptide Clearance Receptor (NPR-C),”J. Biol. Chem., vol. 274, No. 25, pp. 17587-17592 (1999).
Ohbayashi, H. et al., “Neutral endopeptidase 3.4.24.11 Inhibition Potentiates the Inhibitory Effects of Type-C Natriuretic Peptide on Leukotriene D4-Induced Airway Changes,”Clin. Exp. Pharma. Physiol., vol. 25, pp. 986-991 (1998).
Pillai, O. et al., “Polymers in drug delivery,”Curr. Opin. Chem. Biol., vol. 5, pp. 447-451 (2001).
Rousseau, F. et al., “Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia,”Nature, vol. 371, pp. 252-254 (1994).
Schweitz, H. et al., “A New Member of the Natriuretic Peptide Family Is Present in the Venom of the Green Mamba (Dendroaspis angusticeps),”J. Biol. Chem., vol. 267, No. 20, pp. 13928-13932 (1992).
Shiang, R. et al., “Mutations in the Transmembrane Domain of FGFR3 Cause the Most Common Genetic Form of Dwarfism, Achondroplasia,”Cell, vol. 78, pp. 335-342 (1994).
Suda, M. et al., “Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide,”Proc. Natl. Acad. Sci. USA, vol. 95. pp. 2337-2342 (1998).
Vajo, Z. et al., “The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans,”Endocrine Reviews, vol. 21, No. 1, pp. 23-39 (2000).
Van Leeuwen, J.P.T.M. et al., “24,25-Dihydroxyvitamin D3and bone metabolism,”Steroids, vol. 66, pp. 375-380 (2001).
Yamashita, Y. et al., “Concentration of mRNA for the Natriuretic Peptide Receptor-C in Hypertrophic Chondrocytes of the Fetal Mouse Tibia,”J. Biochem., vol. 127, pp. 177-179 (2000).
Yasoda, A. et al., “Natriuretic Peptide Regulation of Endochondral Ossification,”J. Biol. Chem., vol. 273, No. 19, pp. 11695-11700 (1998).
De Feo M.L., et al., “Natriuretic hormone receptors and actions on bone endothelial cells”. Endocrinology. 1993 vol. 133, No. 4, pp. 1759-1766.
Hagiwara H, et al., “cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells”. American journal of Physiology. 1996. vol. 270, pp. C1311-1318.
Samson, W.K. Editorial: “The Power of Two-Molecular Differentiation of the Vascular and Bone Actions of the Natriuretic Peptides”. Endocrinology. 2000. vol. 141, No. 10, pp. 3525-3526.
Vargas S.J., et al., “Effects of atrial natriuretic factor on cyclic nucleotides, bone resorption, collagen and deoxyribonucleic acid synthesis, and prostaglandin E2 production in fetal rat bone cultures”. Endocrinology. Nov. 1989; vol. 125, No. 5, pp. 2527-2531.
Golembo Myriam
Yayon Avner
Borgeest Christina
Kemmerer Elizabeth
ProChon Biotech Ltd.
Winston & Strawn LLP
LandOfFree
Method and composition for treatment of skeletal dysplasias does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treatment of skeletal dysplasias, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treatment of skeletal dysplasias will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839400